Synovial Fluid and Synovium

The synovium is a specialised mesenchymal tissue that lines the non-cartilaginous surfaces of synovial joints. It produces synovial fluid, which nourishes the avascular articular cartilage and lets the joint move with almost no friction.

Synovial fluid is a dialysate of plasma enriched with hyaluronic acid (hyaluronan), a high molecular weight glycosaminoglycan whose viscoelastic properties are essential to joint function.

Where it lies. The synovium lines the joint capsule, the intra-articular ligaments and the bone surfaces not covered by cartilage, reaching the bone-cartilage junction (the tidemark region). It does not cover articular cartilage or the menisci. Folds (plicae) and villi increase its surface area.

What it looks like. A thin membrane, 0.1-0.3 mm thick, with a smooth, glistening surface. It is pink to pale red because it is highly vascular.

View larger

The intima. The lining layer is 1-3 cells thick (20-40 micrometres) and is made of Type A and Type B synoviocytes. It has no basement membrane, a feature unique among the body's membranes, and gaps between its cells let molecules of up to 10-20 nm pass freely. That arrangement permits bidirectional diffusion and rapid fluid exchange, giving the avascular cartilage efficient nutrient exchange. The intima's work is synovial fluid production, cartilage nutrition and debris removal.

The subintima. Beneath the lining is loose connective tissue rich in blood vessels, lymphatics and nerves, providing vascular supply, immune surveillance and structural support. Its vessels supply the joint and form the synovial fluid. It is classified by its predominant tissue:

• Fibrous (collagenous) - near the capsule
• Areolar (loose connective tissue) - near bone
• Adipose - near the fat pads

Blood supply. A rich, anastomosing capillary network in the subintima gives a redundant supply, and its capillaries are fenestrated, allowing fluid and protein exchange. No vessels enter the intima, which is avascular: nutrients diffuse from the subintimal vessels across the intima into the synovial fluid and then to the cartilage. An extensive, lower-pressure venous plexus in the subintima allows fluid to accumulate in inflammation.

Lymphatics. Lymphatic vessels lie in the subintima, not the intima, and drain to regional lymph nodes. They matter for immune surveillance and fluid balance.

Nerves. The synovium has a rich sensory supply.

• Pain fibres, with nociceptors mediating the pain of arthritis
• Mechanoreceptors that detect joint position and movement
• Sympathetic fibres that regulate blood flow

Synovitis. Inflammatory mediators such as IL-1 and TNF-alpha increase capillary permeability, producing an effusion with a high protein content. VEGF drives neovascularisation, and the new vessels bring more inflammatory cells into the joint in diseases such as rheumatoid arthritis.

Synoviocytes

Type A synoviocytes are macrophage-like cells of bone marrow (monocyte) origin. They phagocytose debris, dead cells and immune complexes, present antigen to T cells via MHC-II, and watch the joint for pathogens. In inflammation they secrete IL-1, IL-6 and TNF-alpha.

Type B synoviocytes are fibroblast-like cells of local mesenchymal origin, with long dendritic processes extending into the joint cavity. They are the synthetic cell: hyaluronic acid, the primary source of synovial fluid viscosity, lubricin (proteoglycan 4, PRG4) for boundary lubrication, collagen types I, III and IV for the synovium's own structure, and growth factors (VEGF, FGF) for tissue maintenance.

The two cells work together: Type B creates the lubricating environment and Type A keeps the joint clean. Type A cleans, Type B builds.

Normal fluid. The knee holds 0.3-3.5 mL, the volume varying with joint size. It is clear to pale yellow (straw-coloured), transparent enough to read newsprint through, and highly viscous because of its hyaluronic acid.

Cells. Fewer than 200 WBC/μL, under 25% of them neutrophils and most of them mononuclear: monocytes, lymphocytes and synoviocytes shed from the intima. Normal fluid contains no red cells.

The dialysate. Water makes up 85%, the electrolytes (Na+, K+, Cl-, Ca2+, Mg2+) are similar to plasma, and glucose runs at 90-100% of plasma glucose (50-100 mg/dL). Small molecules diffuse freely from the blood.

Proteins. Total protein is 1-2 g/dL, one-third of the plasma concentration. Albumin predominates and passes through the synovial membrane easily; IgG, IgM and IgA are present at lower concentrations than in plasma. Collagenase and hyaluronidase are normally present only at low levels.

Hyaluronic Acid (Hyaluronan)

Structure. Hyaluronan is a glycosaminoglycan, not a proteoglycan: it has no protein core. It is an unbranched polymer of repeating disaccharides of D-glucuronic acid and N-acetyl-D-glucosamine, up to 25,000 units long, and is anionic (negatively charged) at physiological pH. In normal synovial fluid its molecular weight is 3-4 MDa (3-4 million Daltons) and its concentration 3-4 mg/mL (0.3-0.4%).

Synthesis. Type B synoviocytes make it with plasma membrane-bound hyaluronan synthases (HAS1, HAS2, HAS3), which extrude it directly into the extracellular space as it is synthesised. Turnover is rapid, with a half-life of 12-24 hours in the joint.

Non-Newtonian viscosity. Hyaluronan-rich fluid is shear-thinning. At low shear rates (slow movement) its viscosity is high, which absorbs shock; at high shear rates (fast movement) it is low, which eases movement. This behaviour is ideal for joint function.

View larger

Osmotic properties. Through the Donnan effect, the negative charges attract cations and water. The result is a hydrated gel that resists compression and occupies a large hydrodynamic volume (the excluded volume effect).

Viscoelasticity. The viscous component dissipates energy (damping) and the elastic component stores and returns it. Both contribute to joint function.

What it does in the joint.

• Lubrication - contributes to fluid film lubrication at high speeds
• Shock absorption - high viscosity at low shear dissipates impact forces
• Cartilage nutrition - facilitates nutrient transport to avascular cartilage
• Molecular sieve - restricts diffusion of large molecules and retains growth factors
• Anti-inflammatory - scavenges free radicals and inhibits neutrophil migration

Lubricin (Proteoglycan 4, PRG4)

Structure. Lubricin is a mucin-like glycoprotein encoded by the PRG4 gene, with a molecular weight of 227 kDa that varies widely with glycosylation. A heavily glycosylated central mucin domain, carrying O-linked sugar chains on serine and threonine, lies between terminal globular domains.

Source. Type B synoviocytes and superficial zone chondrocytes both make it, and TGF-beta and mechanical loading increase its production. It is secreted into the synovial fluid, at 50-400 micrograms/mL, and onto the cartilage surface, where it is the primary boundary lubricant, preventing cartilage adhesion and wear at low speeds and high loads.

Joints achieve remarkably low friction, a coefficient of 0.001-0.01, through two complementary mechanisms that operate under different conditions. Between them they cover the full range of joint activity.

Boundary Lubrication

Definition. An adsorbed molecular layer prevents direct solid-solid contact between the surfaces. In synovial joints that layer is lubricin.

How it works.

1. Adsorption - lubricin binds to the articular cartilage surface by its terminal globular domains, forming a monolayer
2. Brush formation - the heavily glycosylated central mucin domain extends perpendicular to the surface as a hydrated, brush-like structure of hydrophilic sugar chains
3. Repulsion - as opposing surfaces approach, the brushes meet: steric repulsion as the sugar chains resist compression, and hydration repulsion as water resists removal from the brushes, together preventing adhesion and solid-solid contact
4. Shear - under sliding, the brushes slide past each other and the hydrated layer acts as the lubricant

When it dominates. Boundary lubrication takes over whenever a fluid film cannot form.

• Static loading - standing still or holding a prolonged posture, the joint stationary under load
• Slow movement and start-up - getting up from a chair or starting to walk, when sliding is too slow for a fluid film to form
• High load - the load exceeds fluid pressure and squeezes the film out
• Consolidation - after prolonged loading has compressed the cartilage

Why it matters. It prevents cartilage wear under low-speed, high-load conditions, protects against adhesive wear, and is critical for start-up friction, the static friction that must be overcome to begin moving. Osteoarthritis is associated with decreased lubricin in the synovial fluid and at the cartilage surface, and that loss of boundary lubrication contributes to wear, especially at low speeds and high loads. Recombinant (exogenous) lubricin is being studied as a potential treatment for osteoarthritis.

Fluid Film Lubrication

Definition. A pressurised layer of fluid separates the opposing surfaces and prevents solid-solid contact. There are two ways to generate the pressure.

Hydrodynamic (wedge film). Sliding creates a converging wedge between the surfaces; fluid is dragged into the narrowing gap, its pressure rises, and the pressure lifts the surfaces apart. It needs tangential (sliding) motion and asymmetric geometry, as in walking and running.

Squeeze film. Rapid loading squeezes the surfaces together and forces fluid out laterally. The viscous fluid resists rapid extrusion, so its pressure rises and it supports the load for a time. It needs normal (perpendicular) loading, as at heel strike or in jumping.

What sets film thickness.

• Viscosity - higher viscosity (hyaluronic acid) gives a thicker film
• Sliding speed - higher speed gives a thicker film
• Load - higher load thins the film
• Surface geometry - incongruent surfaces trap fluid more effectively

The part hyaluronic acid plays. Its non-Newtonian viscosity is high at low shear, supporting the squeeze film, and low at high shear, reducing drag. Its elasticity lets fluid flow back into the gap after the load is removed, and the higher its molecular weight, the better the lubrication.

When it dominates, and when it fails. Fluid film lubrication dominates at high speed (walking, running, cycling), at moderate loads the fluid pressure can support, and between incongruent surfaces that trap fluid easily, such as the femoral head on the acetabulum. It breaks down under a high sustained load that squeezes the fluid out, at slow speeds that generate too little pressure, and when degraded hyaluronic acid leaves the fluid too thin to support a film.

Lubrication in arthritis. In osteoarthritis and inflammatory arthritis, hyaluronic acid is degraded (lower molecular weight, lower concentration) and lubricin with it, impairing both fluid film and boundary lubrication and accelerating wear. The loss of viscosity increases cartilage contact during walking and running. Viscosupplementation with exogenous hyaluronic acid aims to restore fluid film lubrication.

View larger

Additional Mechanisms

These contribute but are less dominant than boundary and fluid film lubrication.

Weeping lubrication. Load compresses the cartilage and interstitial fluid weeps out of the matrix, forming a fluid layer at the surface. Its contribution is minor, and it acts only during initial loading because the fluid quickly redistributes.

Boosted lubrication. As the surfaces approach, small molecules such as water can enter the narrowing gap but the 3-4 MDa hyaluronic acid molecules cannot. Hyaluronic acid therefore concentrates at the gap entrance, raising local viscosity and enhancing load support at the interface. The evidence is mixed: some studies support it, others do not.

Hydration lubrication. Phospholipids such as phosphatidylcholine, from the lipids of synovial fluid and cartilage matrix, form bilayers with hydration shells on the cartilage surface. Like lubricin, they reduce friction by hydration repulsion, and they can achieve a coefficient as low as 0.001.

Cartilage biphasic properties. Cartilage is biphasic, a solid collagen-proteoglycan matrix and a fluid phase. Fluid pressurisation supports the load at first before the matrix takes over, giving time-dependent creep and stress relaxation, and the fluid exuded along the way provides transient lubrication.

Synovial fluid analysis is the gold standard for diagnosing septic arthritis and crystal arthropathy. Cell count, differential, crystals and culture sort the fluid into four categories.

Reading the count. Non-inflammatory fluid comes from osteoarthritis and trauma; inflammatory fluid from rheumatoid arthritis, gout and pseudogout. The septic figure of over 50,000 WBC/μL is the classic one, but counts can overlap with inflammatory arthritis, and the Evidence Base below shows that threshold missing nearly half of septic joints, so a count below it does not exclude infection.

How the Fluid Is Analysed

Gross appearance. Note the colour: clear, yellow, cloudy, bloody or purulent. Hold the tube against newsprint to judge clarity, and test viscosity with the string test: normal fluid forms a 4-6 cm string.

Cell count and differential. A haemocytometer or automated counter gives the total WBC per microlitre and the percentages of neutrophils, lymphocytes and monocytes. Dilute with saline, not acetic acid, which precipitates hyaluronic acid.

Gram stain and culture. Gram stain is 50-70% sensitive for bacterial arthritis. Culture on blood culture agar, chocolate agar and anaerobic media, with prolonged incubation for fastidious organisms, Lowenstein-Jensen medium for TB and Sabouraud for fungi. Inoculate immediately and do not refrigerate.

Crystals. Examine a wet mount on a glass slide under polarised light with a red compensator, recording each crystal's shape, size and birefringence and whether it lies within neutrophils or free. Polarised-light identification is the definitive diagnosis of crystal arthropathy. It separates monosodium urate (gout) from calcium pyrophosphate (pseudogout), and shows other crystals, such as the cholesterol seen in chronic effusions.

View larger

Chemistry. Compare synovial glucose with serum glucose: in septic arthritis it falls below 50% of serum, because bacteria consume it. A synovial lactate over 10 mmol/L suggests sepsis. Protein rises in inflammation, and lactate dehydrogenase (LDH) in both inflammation and infection.

Special tests. Rheumatoid factor may be positive in rheumatoid arthritis. Complement (C3, C4) is low in rheumatoid arthritis, where immune complexes consume it, and in SLE. The mucin clot test, which assessed hyaluronic acid polymerisation (a poor clot meaning degraded HA), is obsolete.

Findings by Condition

The cell counts and neutrophil percentages for these conditions are in the differential diagnosis table below; this table holds what else the fluid shows.

View larger

View larger

View larger

View larger

Rheumatoid Arthritis

The hyperplastic lining. The intima proliferates from its normal 1-3 cell layers to 10-20. Both synoviocyte types proliferate massively, and the fibroblast-like (Type B) hyperplasia, with macrophage-driven cytokine release, forms pannus: invasive granulation tissue that erodes cartilage and bone. That stromal biology is now a therapeutic target (for example, cadherin-11).

The inflammation. T and B lymphocytes, plasma cells and macrophages infiltrate the subintima, and TNF-alpha, IL-1 and IL-6 drive the inflammation and the joint destruction.

Osteoarthritis

The synovitis is mild and low-grade, not as severe as in rheumatoid arthritis. The subintima becomes fibrotic and thickened, and cartilage fragments released into the joint are phagocytosed by Type A synoviocytes. Compared with control synovium, osteoarthritic synovium shows intimal lining hyperplasia, increased subintimal cellularity and vascular proliferation.

View larger

Septic Arthritis

Acute inflammation with massive neutrophil infiltration and a purulent exudate (pus). Bacterial enzymes and neutrophil proteases degrade the cartilage rapidly, and vascular thrombosis can lead to bone infarction.

Pigmented Villonodular Synovitis (Tenosynovial Giant Cell Tumour)

A true neoplasm. Pigmented villonodular synovitis (PVNS) is the classic primary proliferative disorder of synovium, and it is now understood to be a true clonal neoplasm, not merely inflammation. It is grouped with giant cell tumour of tendon sheath as tenosynovial giant cell tumour (TGCT). It is driven by overexpression of CSF1 (colony-stimulating factor 1), frequently through a chromosomal translocation involving the CSF1 gene; the few neoplastic cells then recruit a bulky reactive population of CSF1R-bearing macrophages.

Two forms. The localised form is a discrete nodule: the intra-articular nodular form, or its digit equivalent, giant cell tumour of the tendon sheath. The diffuse form is the classic intra-articular lesion, most often in the knee, then the hip.

Presentation. A young-to-middle-aged adult with insidious monoarticular swelling and pain, mechanical symptoms and recurrent atraumatic, serosanguinous or dark-brown effusion or haemarthrosis.

Imaging. MRI is diagnostic: nodular synovial proliferation that is low signal on both T1 and T2, with characteristic "blooming" artefact on gradient-echo sequences from haemosiderin deposition. The aspirate is classically brown.

Treatment. Synovectomy, arthroscopic for localised disease and open or combined for diffuse disease, with high recurrence in diffuse disease. Radiosynovectomy is an adjunct, and the systemic CSF1R inhibitor pexidartinib is used for diffuse, recurrent or unresectable disease. Untreated diffuse disease causes secondary cartilage and bone destruction.

Synovial Chondromatosis

Cartilage metaplasia of the synovium. Primary synovial (osteo)chondromatosis is the other primary synovial proliferative disorder: a benign metaplasia of the synovial intima producing multiple cartilaginous nodules that ossify and detach as loose bodies. It is a clonal process associated with FN1-ACVR2A gene fusions. Secondary chondromatosis is distinct, its loose bodies arising from a degenerate or osteoarthritic joint or from osteochondral fragments.

Presentation. Monoarticular (the knee most commonly, then hip, elbow and shoulder), with pain, swelling, crepitus, reduced range of motion and locking or catching from the loose bodies.

Imaging. Radiographs show multiple intra-articular calcified or ossified bodies with "ring-and-arc" chondroid mineralisation, characteristically uniform in size in the primary form. MRI or CT shows the non-mineralised cartilage bodies.

Milgram staging.

• Phase I - active intrasynovial disease, no loose bodies
• Phase II - transitional: intrasynovial disease plus loose bodies
• Phase III - free loose bodies, synovial disease quiescent

Treatment. Removal of the loose bodies plus synovectomy to reduce recurrence. Be alert to the rare malignant transformation to secondary chondrosarcoma, suggested by aggressive recurrence and bone destruction.

Gout Flares With a Normal Serum Uric Acid

A gout flare can occur despite a normal serum uric acid. The mechanisms include intra-articular crystal shedding, local microenvironmental changes and NLRP3 inflammasome activation.

View larger

The single most important decision after arthrocentesis is distinguishing septic arthritis from its mimics, because untreated infection destroys cartilage within days.

View larger

View larger

Global Epidemiology

Septic arthritis has a global incidence of roughly 4-10 per 100,000 person-years, rising to 30-70 per 100,000 in patients with rheumatoid arthritis or a prosthetic joint. Staphylococcus aureus is the leading pathogen worldwide; in regions with high HIV/TB prevalence, tuberculous and atypical joint infection are proportionally more common. Crystal arthropathy is rising globally: gout now affects 1-4% of adults in high-income countries (driven by ageing, obesity and metabolic syndrome), with the highest prevalence reported in Oceania. Osteoarthritis with secondary synovitis is the commonest cause of chronic joint effusion across all regions.

Side-by-Side Guidance

Practice Variation and Registry Evidence

Viscosupplementation illustrates marked global practice variation: despite a clear biological rationale (Balazs & Denlinger, above), large meta-analyses found only small symptomatic benefit, leading AAOS, ACR and NICE to recommend against routine intra-articular hyaluronan for knee/hip osteoarthritis, while it remains widely used in parts of Europe and Asia. For prosthetic joint infection, synovial fluid criteria are codified differently by the Musculoskeletal Infection Society (MSIS), the European Bone and Joint Infection Society (EBJIS) and AAOS, producing variation in reported infection rates across national arthroplasty registries. National joint registries (e.g. the Australian AOANJRR, the UK National Joint Registry, and Scandinavian registries) track revision for infection as a key outcome, and consistently identify deep infection as a leading cause of early revision after hip and knee arthroplasty.